← Back to headlines
Johnson & Johnson's Q1 Profit Exceeds Estimates Despite Stelara Sales Disappointment
Johnson & Johnson reported first-quarter profits that surpassed analyst estimates, even as sales of its key drug Stelara fell short of expectations.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
